Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX

In This Article:

With the Canadian economy experiencing a contraction in November and a recent interest rate cut by the Bank of Canada due to tariff uncertainties, investors are navigating a complex landscape. In such times, penny stocks—often smaller or newer companies—can offer intriguing opportunities for those looking beyond established names. While the term "penny stocks" may seem outdated, these investments continue to hold potential for growth and value, especially when backed by strong financials.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Alvopetro Energy (TSXV:ALV)

CA$5.00

CA$180.96M

★★★★★★

Silvercorp Metals (TSX:SVM)

CA$4.73

CA$1.03B

★★★★★★

Mandalay Resources (TSX:MND)

CA$4.68

CA$439.49M

★★★★★★

Pulse Seismic (TSX:PSD)

CA$2.38

CA$120.49M

★★★★★★

Foraco International (TSX:FAR)

CA$2.36

CA$236.24M

★★★★★☆

Findev (TSXV:FDI)

CA$0.50

CA$14.9M

★★★★★★

PetroTal (TSX:TAL)

CA$0.70

CA$628.96M

★★★★★★

NamSys (TSXV:CTZ)

CA$1.00

CA$26.06M

★★★★★★

East West Petroleum (TSXV:EW)

CA$0.04

CA$3.62M

★★★★★★

DIRTT Environmental Solutions (TSX:DRT)

CA$1.14

CA$226.29M

★★★★☆☆

Click here to see the full list of 934 stocks from our TSX Penny Stocks screener.

We'll examine a selection from our screener results.

Oncolytics Biotech

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing pharmaceutical products for cancer treatment, with a market cap of CA$80.93 million.

Operations: Currently, there are no reported revenue segments for this clinical-stage biopharmaceutical company focused on cancer treatment.

Market Cap: CA$80.93M

Oncolytics Biotech Inc., with a market cap of CA$80.93 million, is a pre-revenue clinical-stage biopharmaceutical company focused on cancer treatment. Despite being unprofitable and having less than a year of cash runway, its financial position shows short-term assets exceeding both short- and long-term liabilities. Recent developments include positive safety reviews for the GOBLET study's Cohort 5, evaluating pelareorep in combination with other treatments for pancreatic cancer, which has received regulatory approval from Germany's PEI to continue enrollment. The company's board and management are considered experienced, contributing to its strategic direction amidst ongoing research efforts.

TSX:ONC Debt to Equity History and Analysis as at Feb 2025
TSX:ONC Debt to Equity History and Analysis as at Feb 2025

Nickel 28 Capital

Simply Wall St Financial Health Rating: ★★★★☆☆